New combo therapy aims to extend life for aggressive lung cancer patients

NCT ID NCT07110103

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Mar 08, 2026 · Last updated May 24, 2026 · Updated 11 times

Summary

This study tests whether adding golidocitinib to standard PD-1 inhibitor maintenance therapy can help keep extensive-stage small cell lung cancer from progressing. About 20 adults with untreated advanced disease will receive the combination after initial chemo. The goal is to see if this approach improves how long patients live without their cancer worsening.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Xinqiao Hospital, Third Military Medical University
RECRUITING

Chongqing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

SCLC SCLC, EXTENSIVE STAGE